BioAtla Inc. (BCAB)
NASDAQ: BCAB
· Real-Time Price · USD
0.74
-0.09 (-10.84%)
At close: Oct 16, 2025, 3:59 PM
0.78
5.32%
After-hours: Oct 16, 2025, 07:31 PM EDT
-10.84% (1D)
| Bid | 0.69 |
| Market Cap | 43.24M |
| Revenue (ttm) | 11M |
| Net Income (ttm) | -59.52M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -0.67 |
| Forward PE | -0.67 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 0.78 |
| Volume | 1,438,058 |
| Avg. Volume (20D) | 941,981 |
| Open | 0.80 |
| Previous Close | 0.83 |
| Day's Range | 0.66 - 0.86 |
| 52-Week Range | 0.24 - 2.52 |
| Beta | 1.02 |
| Ex-Dividend Date | n/a |
About BCAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+13.92%
BioAtla shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago
+24.69%
BioAlta shares are trading higher after the company provided updates from its Phase 2 trial of Ozuriftamab Vedotin.
